Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

This publication has 25 references indexed in Scilit:

• Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100
  Drug Metabolism and Disposition, 2007
• Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B
  Circulation, 2006
• Effects of Colesevelam Hydrochloride on Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein When Added to Statins in Patients With Hypercholesterolemia
  The American Journal of Cardiology, 2006
• An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
  Journal of Lipid Research, 2005
• Familial Hypercholesterolemia and Coronary Heart Disease: A HuGE Association Review
  American Journal of Epidemiology, 2004
• Optimal low-density lipoprotein is 50 to 70 mg/dl
  Journal of the American College of Cardiology, 2004
• CP-346086
  Journal of Lipid Research, 2003
• Inhibition of Microsomal Triglyceride Transfer Protein: Another Mechanism for Drug–Induced Steatosis in Mice
  Hepatology, 2003
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001